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ABSTRACT 
 
In according to the last available data, cancer is the second cause of 
death in many countries, following only cardiovascular diseases. As the 
risk of cancer increases in the elderly and also because of other factors 
such as tobacco, low vegetable and fruit intake, pollution and that 
develop countries are aging and are notorious for their “unhealthy 
lifestyle”, soon the cancer will be the first “killer” in the world: new 
treatments approaches are needed in order to replace or combine the 
classical treatments such as surgery, radiotherapy and chemotherapy. 
Among the new therapeutic approaches, one emerging and promising 
field is the immunotherapy, which aim to elicit de novo anti-tumour 
response and/or boost the pre-existing anti-tumour immunity.  
 
The cancer immunotherapy consists of different approaches such as 
oncolytic viruses, which are able to replicate only in the cancer cells, 
and the immune checkpoint inhibitors, which revert or prevents the T-
cell exhaustion. Both approaches showed efficacy in the eliciting anti-
tumour immune response, but there are solid tumours poor 
immunogenic and immunosuppressive that could benefit from a 
combination of these treatments, such as Triple-negative breast cancer. 
 
Triple-negative breast cancer (TNBC) is an aggressive subtype of 
breast cancer currently resistant to available treatment approaches; 
therefore, in the present study, we decided to evaluate the efficacy of a 
tumour-specific vaccine platform based on peptide-coated oncolytic 
adenovirus (PeptiCRAd) that we had previously developed for different 
tumours. 
 
PeptiCRAd is a versatile and rapid system to adsorb tumour-specific 
major histocompatibility complex class I (MHC-I) peptides onto the 
viral surface to drive the immune response toward the tumour epitopes. 
In fact, the combination in a single treatment of the adjuvancy of the 
virus with the immunological targeting of tumour-derived peptides 
converts the powerful anti-viral immune response obtained with viral 
vaccines into a more efficient anti-tumoural response.     
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In the present work, we adapted PeptiCRAd in a poor immunogenic 
and high immunosuppressive tumour model such as TNBC and for the 
first time we improved the PeptiCRAd platform adding on the same 
oncolytic vaccine tumour peptides restricted for both MHC-I and 
MHC-II in order to harm TCD8+ and TCD4+ lymphocytes and to obtain 
a more efficient and complete immune response.  
 
Tumour cells evade immune recognition and destruction by down 
regulating MHC-I and up-regulating PDL-1. Thus, we chose and 
characterized human (MDA-MB-436) and mouse (4T1) triple negative 
breast cancer cell lines for the expression of MHC-I, MHC-II and PDL-
1, demonstrating that they are a solid model for our immunotherapeutic 
approach. As PeptiCRAd relies on Ad-5-D24-CpG, we demonstrated 
that has similar cytopathic effect (CPE) to Ad-5/3-D24, already 
validated in human model of TNBC.  
 
In the first set of in vivo experiments, we observed that oncolytic 
vaccines coated with a combination of MHC-I and MHC-II peptides 
induced a stronger response compared to those coated with either 
MHC-I or MHC-II peptides. Interestingly, we also observed that 
administration of mixture of equal concentrations of oncolytic vaccines 
coated with MHC-I or MHC-II peptides is less efficient compared to 
the double coated formulation: therefore, we concluded that MHC-I and 
MHC-II peptides have to be loaded on the same surface to maximize 
the effect. 
 
Next, we evaluated the synergistic effect of administration of the 
PeptiCRAd-D.C. preparation with anti-PDL1 antibody in TNBC; our 
results clearly demonstrated a significant improvement of the oncolytic 
vaccine efficacy when administrated in combination with anti-PDL1.  
 
Finally, we translated our treatment in relevant human model of TNBC, 
we performed a Cytotoxic T-lymphocytes (CTL) killing assay in a co-
culture experiment with human tumours. In vitro we pulsed with our 
vaccine human peripheral blood mononuclear cell (PBMCs) HLA-
matched with the tumours and we added them to the tumour sample; 
cancer cells viability was then evaluated.  The tumour peptides selected 
in the above experiment for the PeptiCRAd preparation were selected 
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from well-known human triple negative breast cancer antigens. In 
addition, one tumour peptide was selected by using an improved 
version of ligandome analysis. 
 
In conclusion, we have demonstrated for the first time the efficacy of 
PeptiCRAd technology based oncolytic vaccine in a challenging model 
of TNBC; in addition, we observe that vaccine coating with a 
combination of MHC-I and MHC-II restricted peptides is more 
effective than the previously used MHC-I restricted peptides coating, 
leading to a further improvement of the system.
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1. INTRODUCTION 
 
1.1 Cancer: a global health problem  
 
Tumour is the result of uncontrolled cell proliferation and can arise 
from any kind of cells of our body, so that we have at least 200 different 
type of tumours. We distinguish benign and malignant tumour. 
 
The benign tumour is located at its original site, not invades the 
surrounding tissues either spreads in different part of the body; the 
malignant tumour is properly referred as cancer and owns both 
capacities of invading surround tissues and spreading in different parts 
of the body.  
 
At cellular level, cancer is defined as a multistep process, in which the 
cells, because of genetic and epigenetic changes, mutate and a clone of 
tumour cells acquires selective advantages among the other cells such 
as evading growth suppressors. Other hallmarks of cancer consist of 
self-sustaining proliferative signalling, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, 
resisting cell death, deregulating cellular energetics, genome 
instability, avoiding immune system and tumour-promoting 
inflammation (Hanahan and Weinberg 2011) . Therefore, the cancer is 
a complex disease and especially in the advanced stages difficult to 
eliminate. 
 
According to the last data released by World Health Organization 
(WHO) (Ferlay et al. 2015) cancer is the second leading cause of death 
in the world, following only cardiovascular diseases; the principle risk 
factors are behaviour related and include smoking, alcohol, low 
vegetable and fruit intake, lack of physical activity and ageing; all these 
factors are being common, in particular, in the develop countries. In 
fact, the number of new cases of cancer is expected to rise by about 
70% over the next 2 decades. Nevertheless, the cancer has a strong 
economic impact: in 2016, it has been estimated a total cost, 
comprehensive of oncology and supportive care, of 113 billion at a 
growth rate of 11.6% (imshealth.com/global oncology trends 2017).  
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It is clear that the cancer represents a public health emergency and in 
order to eradicate it new therapies are urgently needed; in fact, the 
actual treatment approach consists of surgery, radiotherapy and 
chemotherapy with their well know side effects; however, in the last 
years is emerging a new field with encouraging clinical results: the 
cancer immunotherapy. 
 
 
1.2 Cancer Immunotherapy 
 
The cancer immunotherapy is defined as the science that harness the 
immune system to fight the cancer. Even if the immunotherapy is 
attracting the public attention only in the last years, it goes back as far 
a 100 years ago.  
 
The history of immunotherapy begins in 1891 with the Coley´s toxins; 
William Coley noticed that a 31-old man with a terminal sarcoma, had 
a completely cancer regression, as result of the erysipelas, a skin 
infection caused by streptococcus bacterium. Following this 
observation, Coley injected the erysipelas bacterium in the tumour of a 
man with a terminal neck cancer; the patient survived cancer free for 
eight years. 
 
In the early 20 centuries, still little was known about the immune 
system and also less about the interplay with the cancer. The Coley´s 
toxins worked sporadically and no one knew “how”, so that the Coley´s 
work was forgotten.   
 
In 1957 Burnet and Thomas introduced for the first time the concept of 
the immune surveillance (Burnet 1957), concept developed later in 
immune editing (Dunn et al. 2002).  
 
The immune surveillance is the process in which the immune system 
recognizes and eradicates cancer cells; however, this concept describes 
only the protecting host function of the immune system in the early 
stages of the cancer transformation; later, in order to include also the 
tumour sculpting activity on the immune system, the concept was 
developed from immune surveillance to immune editing. 
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The immune editing is described with the acronym “three E´s” 
(Elimination, Equilibrium and Escape). 
 
The elimination phase coincides with the immune surveillance, in 
which the immune system recognizes and eliminate the cancer cells.  
 
The equilibrium phase is the process by which the immune system 
controls but not fully extinguishes the tumour cells genetically unstable 
and highly mutated. New tumour clones arise during the process and 
are subject to a strong selection: the cells that survive to the immune 
attack will be able later to escape to the immune control. This is the 
longest phase of the immune editing and require years. 
 
The escape phase is the process wherein the immunological sculpted 
tumour expands in uncontrolled manner (Dunn et al. 2002; Kim, Emi, 
and Tanabe 2007).  
 
During the years, several breakthroughs have been achieved in the field 
of the cancer immunotherapy: discovery of the dendritic cells (DC) 
(Steinman and Cohn 1973),  discovery of MHC-I restricted T-CD8 
(Zinkernagel and Doherty 1974a) (Zinkernagel and Doherty 1974b), 
first administration of autologous T-cell (Rosenberg et al. 1985), first 
study with tumour necrosis factor (TNF) in melanoma and sarcoma 
(Lienard et al. 1992) until the first vaccine approved by the FDA to 
prevent the cancer caused by the human papilloma virus (HPV) (Kenter 
et al. 2009). 
 
However, the cancer immunotherapy is still growing and the aim is 
inducing the anti-tumour response, stimulating the person´s immune 
defences. To this end two main approaches have been developed: 1. 
non-antigens specific and 2. antigens specific strategies.  
The first approach is comprehensive of therapies such as non-specific 
immune stimulation (use of cytokine like TNF and interleukine2 (IL-
2)) and inhibition of immune check point; 
The second approach educates the immune system to recognize the 
tumour as non-self by using techniques like adoptive cell transfer and 
therapeutic vaccination (Lesterhuis, Haanen, and Punt 2011).   
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1.2.1 Cancer and Immune checkpoints  
 
Immune checkpoints are molecules involved in the checking and in the 
balance of the immune system by controlling its activation. Under 
physiological conditions, the immune checkpoints maintain the self-
tolerance, avoiding autoimmunity reaction and protecting the tissue 
from collateral damages when the immune system is activated in 
response to  infections or other pathogens (Pardoll 2012). 
 
The cancer cells dysregulate immune checkpoints, as one of the 
mechanism of resistance, in particular against the T-cells. In fact, T 
cells selectively recognize peptides derived from proteins in all cellular 
compartments: TCD8+ cells, also known as CTLs, identify and kill 
antigen-expressing cells; TCD4+, also known as helper T cells, 
orchestrate diverse immune responses, by integrating adaptive and 
innate effector mechanisms: hence, TCD8+ and TCD4+ are the main 
protagonists in the orchestrating the anti-tumour immune response 
(Pardoll 2012; Sharma and Allison 2015b, 2015a).  
 
The blockade of immune checkpoints, by using monoclonal antibodies, 
is currently under investigation in order to unleash the T-cell mediated 
anti-tumour response. The immune checkpoint inhibitors work 
blocking the inhibitory pathway and are mainly focus on two immune 
check points: CTLA-4 and PD-1/PD-L1(table 1).  
 
Anti-CTLA-4 is the first immune checkpoint inhibitor used for the 
treatment of cancer, discovered and tested by Allison and colleagues 
(Leach, Krummel, and Allison 1996); biologically CTLA-4 counteracts 
the activity of the T cell co-stimulatory receptor, CD28, with which 
shares the ligands CD80 (B7.1) and CD81 (B7.2) in the lymphoid 
compartment. Thus, CTLA-4 regulates the T-cell activation. 
 
Unlike CTLA-4, the pathway PD-L1/PD1 regulate the effector T- cells; 
hence, PD1/PD-L1 occur in the late stages, when the T-cells are already 
in the tumour. In the present work, we focused our attention on this 
pathway. 
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Table 1 Source: 
https://www.drugs.com/slideshow/immunecheckpoint-inhibitors-1249 
 
 
 
 
 
Name Target Indication 
Yervoy 
(ipilimumab) from 
Bristol Myer 
Squibb 
CTLA-4 Advanced melanoma 
Keytruda 
(pembrolizumab) 
from Merck 
PD-1 Advanced melanoma, 
NSCLC, Hodgkin´s 
lymphoma and head and 
neck cancer 
Opdivo 
(nivolumab) from 
Bristol Myer 
Squibb 
PD-1 Advanced melanoma, 
advanced NSCLC, advanced 
renal cell cancer, bladder 
cancer, Hodgkin’s 
Lymphoma and squamous 
cell carcinoma of the head 
and neck 
Tecentriq 
(atezolizumab) 
from Genentech 
PD-L1 Advanced bladder cancer 
and NSCLC 
Bavencio 
(avelumab) from 
Pfizer 
PD-L1 MCC and bladder cancer 
Imfinzi 
(durvalumab) from 
AstraZeneca 
PD-L1 Advanced bladder cancer 
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1.2.2 PD-1/PD-L1: immunosuppressive pathway in the tumour bed 
 
The pathway PD-1/PD-L1 fine tunes the immune response, maintaining 
the self-tolerance, mainly regulating the T-cell activity and it is made 
of PD-1(CD279) and its ligand PD-L1(B7-H1, CD274) and PD-L2 
(B7-DC, CD273) (Riley 2009). 
 
PD-1, encoded by the PDCD1 gene, is a receptor and, in particular, it 
is a type I transmembrane protein of 268 amino acids, member of the 
extended CD28/CTLA-4 family T-cell regulators (He et al. 2015).  
 
The structure includes an extracellular IgV domain, a transmembrane 
region and an intracellular tail. This latter consists of two regions: the 
immune receptor tyrosine-based inhibitory motif (ITIM) and the 
immune receptor tyrosine-based switch motif (ITSM). The ITSM is 
involved in the T-cell inhibitory function. PD-1 is mainly expressed on 
the surface of T-cells, B-cells, activated monocytes, natural killer (NK), 
DC and TILs (He et al. 2015; Ceeraz, Nowak, and Noelle 2013). In 
addition is also expressed on T reg, facilitating their proliferation and 
the inactivation of immune system (Francisco et al. 2009).   
 
PD-L1 was described for the first time at Maya Clinic and identified as 
B7-H1  (Dong et al. 1999); later, it was discovered to be a ligand of PD-
1, from which take the actual name PD-L1.  
 
PD-L1 is a transmembrane protein of 290 amino acids and consists of 
extracellular domain (signal sequence, IgV-like domain, IgC-like 
domain), transmembrane domain and intracellular domain. This latter 
is made of only 30 amino acids conserved across diverse species and 
without a known function (Keir et al. 2008). The same structure has 
been described for PD-L2.  
 
The two ligands of PD-1 differ in their expression pattern; PD-L1 is 
constitutively express on T and B cells, DC, macrophages, 
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mesenchymal stem cells (MSCs), bone marrow derived mast cells 
(BMMC) and also on a wide range of non-hematopoietic cells; instead 
PD-L2 expression is only inducible on DCs, macrophages, BMMC and 
resting peritoneal B1 cells(Keir et al. 2008).  
 
PD-L1 is induced by pro inflammatory molecules such as types I and 
II IFN-γ, TNF-α, lipopolysaccharide (LPS), granulocyte macrophage 
colony stimulating factor (GM-CSF), vascular endothelial growth 
factor (VEGF), IL-10 and IL-4;  
 
Activated type 1 T cells produce IFN-γ and TNF-α, on the other hand 
cancer stromal cells release GM-CSF and VEGF; hence, the tumour 
microenvironment upregulates PD-L1 expression, creating an effect 
called “adaptive immune resistance”, since the tumour protects itself by 
inducing PD-L1 in response to IFN-γ produced by activated T cells and 
in response to GM-CSF and VEGF produced by the cancer stromal 
cells (He et al. 2015). 
 
The pathway PD-L1/PD-1 modulate the immune response in 
physiological condition and in cancer, by diverse mechanisms (Fig.1): 
 
1. Apoptosis: the PD-L1 engagement to its receptor PD-1 induces 
the phosphorylation of two intracellular tyrosines, recognized 
and bind by two phosphatases: SH2-domain containing tyrosine 
phosphatase 1 (SHP-1) and 2 (SHP-2). The binding of SHP-1 is 
weaker than SHP-2: in general, the signalling is modulated 
through SHP-2. The SHP-2 inhibits PI3K that in turn cannot 
activate AKT. This latter cannot induce Bcl-xL, anti-apoptotic 
gene (Keir et al. 2008; He et al. 2015). 
 
2. Anergy and Exhaustion: anergy and exhaustion occur when the 
effector T cell lose its effector function during chronic 
infections and cancer. The exact mechanism is not completely 
understood, but it has been observed that they occur in response 
to high level of PD-L1(Pauken and Wherry 2015) that inhibits 
the expression of GATA3, Tbet and Eomes, all transcription 
factor associated to the effector T cell (Nurieva et al. 2006). 
 
 
 
11 
3. Treg induction: The PD1/PD-L1 interaction induces the down-
regulation of AKT/mTor, inducing the expression of 
transcription factor Foxp3, characteristic of Treg cells. 
Furthermore, PD1/PD-L1 downregulates the phosphorylation 
of p42/ERK, hence MAP kinase cascade signalling, promoting 
the Treg development (Francisco et al. 2009).  
 
4. Anti-proliferative effect: PD1/PD-L1 interaction induces the 
down-regulation of AKT/PI3K and Ras/MEK/ERK signalling 
with accumulation of p27 and p15 that restrain the T cell in the 
G1 phase of the cell cycle (Patsoukis, Sari, and Boussiotis 
2012). The PD1 engagement reduces also the phosphorylation 
of PCK-theta that is essential for IL-2 production (Sheppard et 
al. 2004).   
 
5.  Inhibition of T cell activation: PD1/PD-L1 blocks also the 
signalling downstream triggered by the interaction antigen 
(Ag)/MHC; in fact, PD1 ligation induces the de-
phosphorylation of ZAP70/CD3z,  blocking the downstream 
signalling activation pathway CD3 mediated (Parry et al. 2005). 
 
 
The cancer environment produces immunosuppression in the tumour 
bed by inducing PD-L1; therefore, cancer characterized by immune 
infiltration benefit from treatments with immune check point inhibitors. 
Nevertheless, as another resistance mechanism, the cancer can loss the 
immune infiltration, and in this case of “cold” tumour, the immune 
check point inhibitors results ineffective. 
 
Nowadays, the main aim is converting the tumour from “cold” (lack of 
immune infiltration) to “hot” (presence of immune infiltration) and to 
this end it’s necessary to identify which is the best standard care therapy 
to combine with immune checkpoint inhibitors and how;  
 
Among the several combination approaches proposed, oncolytic 
viruses result the best way to stimulate the T cell infiltration in the 
tumour bed; in fact, talimogene laherperepvec (T-VEC), oncolytic 
herpes virus, is currently studied in combination with ipililmumab 
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(anti-CTLA4) in a phase II trial (NCT01740297) and with 
pembrolizumab (anti-PD1) in a phase Ib/III trail (NCT02263508) in 
melanoma patients (Swart, Verbrugge, and Beltman 2016). 
 
T-VEC (trade named Imlygic, Amgen) is a herpes virus modified to 
express GM-CSF and approved by FDA in October 2015 to treat 
melanoma patients: T-VEC represents the first drug, belonging to 
oncolytic viruses’ class, approved in West to treat cancer patients 
(https://www.fda.gov/newsevents/newsroom/pressannouncements/uc
m469571.htm). 
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Tumor
T-cell
APC
PD-L1/2
PD-1
MHC
TCR/CD3
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Y
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Bcl-xL, mTOR, IL-2
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P
Cytokines
Foxp3
Figure 1 PD1/PD-L1 interaction decreases the TCR signalling. The T-cell 
activation requires three signals: contact peptide/MHC complex, 
CD28/B7.1/2 and cytokines, all signals from APC. The PD-1 engagement 
leads to the downregulation signalling pathway mediated by TCR in 
different ways; one of the mechanisms PD-1 mediated is the de-
phosphorylation of PI3K with the AKT downregulation pathway. 
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1.3 Oncolytic Viruses 
 
Oncolytic viruses (OVs) refer to a wide range of natural or genetically 
modified viruses that are able to induce cancer cells lysis by different 
mechanisms during their life cycle, except the retrovirus, that can be 
rendered lytic by toxic transgene expression (Lawler et al. 2017). 
 
The wild type OVs in clinical are few: reovirus and coxsackievirus, 
both with human host and OVs with animal host such as Newcastle 
disease virus (avian), parvovirusH1 (rat) and vesicular stomatitis virus 
(VSV) (insects, horses, cows and pigs). On the other hand, most of the 
OVs are engineered to improve the cancer cell selectivity; for instance, 
Herpes simplex virus 1 (HSV1) brings the deletion in ICP6 gene; this 
deletion allows the HSV1 replication in the cells with inactivation of 
the p16INK4A, a tumour suppressor, often mutated in cancer cells; 
similarity, OAd brings a deletion of 24 base pairs in E1A gene, that 
allows the virus replication only in the cells with inactivation in 
oncosuppressor retinoblastoma (Rb), commonly mutated in the cancer 
cells (Lawler et al. 2017). 
 
Even if during the years most of the researches were focused on the 
identification and/or engine viruses selectively replicative in cancer 
cells, nowadays it is often appreciated an immune component in their 
action mechanism, so that OVs are currently considered 
immunotherapy agents, not anymore components of the virotherapy, 
but of the immune virotherapy. 
 
In fact, OVs induce systemic innate and tumour-specific adaptive 
immune responses; following the cancer cell lysis, tumour associated 
antigens (TAA) are released; TAA promote the tumour-specific 
adaptive immune response, by inducing tumour regression also in sites 
far from virus infection. The lysis cause also the release of viral 
Pathogen Associated Molecular Pattern (PAMP) such as LPS, dsRNA, 
CpG islands, recognized by receptor of innate immune response called 
Pattern Recognition Receptors (PRR), present in APC. 
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In addition, Danger Associated Molecular Pattern (DAMP) (for 
example high mobility group box 1 (HMGB1), ATP, uric acid, 
calreticulin) and cytokines (IFN I, IFNg,TNFa, IL-12) are also 
released, inducing the maturation and the activation of the APCs. These 
activate antigen specific TCD4+  and TCD8+    responses; upon antigen 
specific activation, the TCD8+ can expand in CTLs and migrate to the 
sites with established tumour growth, in which they start the anti-
tumour specific immune response (Kaufman, Kohlhapp, and Zloza 
2015). 
 
Hence, OVs infect and lysis the cancer cells, with release of TAA, 
PAMP, DAMP and cytokines; in particular, TAA in combination with 
cytokines and DAMP are able to induce and sustain anti-tumour 
immune response.  
 
 
1.3.1 Adenoviruses 
 
The Adenoviruses are the most common vectors used in the gene 
therapy and we also used them in the present work for our experimental 
approaches.  
 
The Ad were described for the first time by Rowe and colleagues during 
a study of the growth of human adenoid tissue; they observed the 
presence of a transmissible agent, that was able to induce tissue and cell 
degeneration; because of that, they called this agent the “Adenoid 
Degeneration agent “ “A.D. agent” (Rowe et al. 1953), from which take 
the actual name “Adenovirus”. 
 
The Ads belong to the genus Mastadenovirus and are subdivided in 
seven species (A-G), based on their ability to agglutinate erythrocytes 
(Rosen 1960); in turn, the species consist of 68 serotypes; the 
classification of 1-51 Ads serotypes relies on the traditional serological 
methods in composition and pathogenicity, whereas the classification 
of 52-68 Ads serotypes is based on genomic sequencing and 
bioinformatics analysis.  
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Typical adenoviral infections occur in children, are self-limiting and 
consist of different clinical events, including conjunctivitis, 
gastroenteritis, hepatitis, myocarditis and pneumonia (Ghebremedhin 
2014).  
 
As Ads infect dividing and not-dividing cells, the most common 
platforms based on oncolytic viruses use Ad; in particular serotype 5 
Ad (Ad5) is a popular vector in the oncolytic immunotherapy, since its 
biology is well known and it is relatively harmless; Furthermore, Ad5 
is classified as specie C and among the other viruses, it is the more 
effective in the binding of the coxsackie and adenovirus receptor (CAR) 
(Shashkova, May, and Barry 2009); finally, the Ad5, being genetically 
well characterized,  can be easily manipulated and modified to express 
immune-stimulatory molecules, for example cytokines (Choi et al. 
2012). 
 
1.3.1.1 Structure 
 
Adenoviruses have a size in range from 65-80nm in diameter and a 
molecular weight of ~150MDa; the virions are non-envelop (no outer 
lipid layer) with an icosahedral protein capsid, containing a linear 
duplex DNA genome of approximately 36,000 base pairs and internal 
proteins (Wold and Toth 2013).  
 
The capsid consists of 252 capsomeres, subdivided in 240 hexons and 
12 pentons, corresponding to the twelve icosahedral vertices ; the base 
of the penton is made up of a fiber, which length varies among the 
serotypes; the fiber consists of three domains: a short N-terminal tail 
that attaches the fiber to the penton base, a shaft domain comprised of 
a repeating triple b-spiral motif and a globular knob domain, required 
for the receptor binding; in particular, the binding occur at lateral 
surface of the knob rather than at its extreme distal portion (Campos 
and Barry 2007; Smith et al. 2010).  
 
In detail, the icosahedral capsid contains seven different proteins: II, 
III, IIIa, IV, VI, VIII and IX; in particular, the icosahedron is composed 
by twenty facets, made up of 240 trimers of hexon (protein II), whereas 
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the penton is a complex of proteins III and IV. The virion stabilization 
is mediated by IIIa, VI, VIII and IX, which are proposed to be the 
“cement” of the structure (Smith et al. 2010). 
 
The viral genome inside the capsid encodes 35 proteins and it is 
structurally associated and condensed with the proteins V, VII and X 
(µ) and a two copies of a 55KDa terminal protein (TP) is covalently 
linked to each 5´ends of Ad DNA (Smith et al. 2010) (Wold and Toth 
2013; Campos and Barry 2007) (Figure 2). 
 
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
 
 
Figure 2 Adenovirus virion structure: capsid and core. 
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1.3.1.2 Life cycle 
 
The viruses are defined obligate intracellular parasites: they completely 
lack the machinery needed for their reproduction, so that they depend 
on cellular machinery of the host for viral gene expression and for 
synthesis of proteins. The Ad are not an exception. 
 
In fact, he adenoviral life cycle starts with the cellular infection, 
mediated by the binding of distal knob domain of adenoviral fiber on 
the host cells receptors; during their evolution, the Ad have exploit 
diverse cell-surface molecules interaction, which determined the actual 
adenoviral tropism. Most of Ad subgroups recognize the CAR receptor, 
a type 1 transmembrane protein, belonging to the immunoglobulin 
family, involved in the formation of the cellular thigh junction and 
localized at level basolateral (Campos and Barry 2007).  
Instead, the adenoviral subgroup B, which includes Ad3, uses either 
CD46, CD80/CD86, an unidentified glycoprotein receptor or a 
combination of these. In addition, it has been observed that Ad5 
interaction with certain cellular types can be favourite by the presence 
of heparan sulfate proteoglycans (HSPGs) (Campos and Barry 2007).  
 
After the binding to the primary receptor, the motif Arg-Gly-Asp 
(RGD) on the adenoviral base penton interact with the cellular an b3 
and an b5 integrins; this binding triggers the signalling cascade and the 
clathrin-mediated endocytosis (Russell 2009).  
 
Following the internalization, the virions, inside the vesicles, enter in 
the endosomal pathway; the acid endosomal environment induces 
irreversible structural changes in the penton and capsid: the virus 
became uncoated (in this stage the virus is surrounded only by hexons). 
The modified conformation allows the endosomal escape, in which the 
virus passes from the vesicles in the cytoplasm. Here, the partial 
adenoviral capsid binds the dynein, a cellular motor protein, that bring 
the virion to the microtubule organizing centre (MTOC) close to the 
host cellular nucleus. By an unknown mechanism, the virion enters 
through the nuclear pores in the nucleus, where it initiates the 
transcription of the early genes (E1-E4), and late genes (L1-L5), 
respectively before and after the DNA replication. 
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E1A is the first protein expressed and it is involved in the modulating 
the cellular metabolism to facilitate the virus reproduction; then, it 
influences the proteins that control the cell cycle; for example, E1A 
binds Rb and makes free the transcription factor E2F, favouring the 
enter of the host cell in S phase of the cell cycle. In sequence are 
expressed the following genes products: E1B that control the late virus 
messenger RNA (mRNA) transcription, stabilize p53 and function as 
important effector of inflammation in vivo; E2 that provide the 
machinery for the DNA replication; E3 inhibits the anti-viral host 
defence response; E4 that facilitate the virus mRNA metabolism and 
the transcription of the late genes. After the DNA replication, the L1-
L5 are expressed: they are structural proteins that allow the virion 
formation.  
The adenoviral life cycle ends with the lysis of the host cells and the 
release of the new virions. The early phase requires 6-8 hours and the 
late phase 4-6 hours (Russell 2000). 
 
1.3.1.3 Modifications for oncolytic strategies 
 
As previously mentioned, Ads infect their target cells, replicate inside 
and, in the end, induce the lysis of the host cells; during the years, this 
lytic property has been exploited to kill the cancer cells. 
 
In order to use Ads as oncolytic agents, two main strategies have been 
used: promoting the virus-replication restricted to cancer cells and 
enhancing tropism towards the tumour, modifying the structural 
components (trasductional targeting) or the gene expression 
(transcriptional targeting) (Barnett et al. 2002). 
 
One approach to generate a replication-selective Ad is the deletion of 
viral genes needed for the correct replication in normal cells, but not in 
cancer cells. Oncorine (H101) in China and ONYX-015 (dl/1520) (Kirn 
2001) in USA are the first oncolytic Ad developed following this 
strategy: in both cases the OAd has been generated by deleting the E1B 
gene. This modification allows the OAd to infect and kill p53-deficient 
cancer cells; however, only 50% of the cancer cells own p53 mutation 
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and the lack of E1B reduces the replication and production of Ad, that 
in turn reduces the anti-tumour efficacy (Choi et al. 2012).  
Since E1A is the first gene expressed, after the virus infection, one of 
the most useful modification to generate the OAd is the 24-base pair 
deletion (D24) in the pRb binding site of the E1A region (Fueyo et al. 
2000). In normal cells, the Ad-D24, because of that deletion, is unable 
to bind Rb, that in turn form a complex with E2F, resulting in the 
inhibition of E2F-mediated activation genes involved in the viral 
replication and cell cycle progression. Instead, in cancer cells pRB/p16 
pathway is often inactivated (Knudsen and Wang 2010) and this allow 
Ad-D24 to replicate in malignant cells (Fueyo et al. 2000). 
 
In addition to genetic manipulations, several approaches have been 
used to enhance the immune-stimulation OAd mediated, such as 
Ad5D24 engineered with 18 immunostimulatory islands 
(Ad5D24CpG) (Cerullo et al. 2012) or engineered with GM-CSF 
(Ad5/3D24-GM-CSF, Oncos 102) (Kuryk et al. 2017). Then, another 
approach is the generation of chimeric Ad-5/3-D24, in which the knob 
domain belongs to Ad3 and tail and shaft domains of Ad5; this chimeric 
Ad is able to infect a large spectrum of cancer cells compare to Ad5: 
the primary binding is mediated via Ad3 receptor and the following 
internalization achieved by domain of the penton base of Ad5 
(Krasnykh et al. 1996). Finally, the inclusion motif such as RGD and/or 
poli-lysines (pK7) in the adenoviral capsid, increase the infection, 
making the virus able to infect positive and negative CAR cells (Wu et 
al. 2002; Pesonen et al. 2012). 
 
 
1.3.1.4 Anti-viral and anti-tumour immune responses  
 
The infection Ad or OAd mediated induces innate and adaptive anti-
viral immune response, being virus recognized as “non-self” by DCs 
and macrophages, the frontline against the viral infection (Akira, 
Uematsu, and Takeuchi 2006). Following the virion internalization, the 
adenoviral un methylated CpG dsDNA (member of PAMP family) in 
the endosomal compartment binds Toll Like Receptor 9 (TLR9, 
member of the PRR family); this interaction leads via Myd88 and/or 
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TRIF to the production of type I IFNs and to other pro-inflammatory 
cytokines (for example IL-6, IL-12, TNF-a) (Nociari et al. 2007). 
In particular, type I INFs play a pivotal role in the innate and adaptive 
anti-viral immune response: type I INFs promote DCs maturation, the 
survival of activated anti-viral T cell and the production of neutralizing 
antibodies (NAbs) in response to adenoviral infection, activating B-
cells and TCD4+ (Zhu, Huang, and Yang 2007; Huang and Yang 2009) 
The cytokines released function as chemoattractant for macrophages, 
neutrophils and NK, that are recruited at infection site and can directly 
engulf the virus (Thaci et al. 2011). 
Furthermore, as DCs and macrophages are professional APC, they 
uptake, process and cross-present adenoviral components in the context 
of MHC-I and MHC-II, activating the TCD8+ and TCD4+, respectively. 
Whereas TCD8+ directly kill the cell infected with the virus, the TCD4+ 
collaborate with B-cells for the antibodies production (Heath and 
Carbone 2001). 
 
In addition to anti-viral immune response, OAds trigger a strong anti-
tumoural immune response. Indeed, OAds induce cancer cell lysis, 
enhancing the availability of TAA and unclosing hidden tumour 
antigens to APCs (for example DCs); then, the lysis releases DAMPs 
(uric acid, HSP) that being danger signals, activate DCs (Prestwich et 
al. 2008; Pesonen, Kangasniemi, and Hemminki 2011). 
 
Hence, DCs take up the TAA, integrate the danger signals and present 
the antigen in a correct costimulatory context to activate the harm of 
adaptive immune response, in particular effector TCD8+. Although 
TAA are exogenous antigens and should be present in the context of 
MHC II to activate TCD4+ immune response, however the DCs can 
present these antigens in the context of MHC I, activating TCD8+; this 
biological event is termed “cross-presentation” and the viral signal 
seems a strong inducer of the cross-priming (Schulz et al. 2005). 
 
OAds induce the anti-viral innate and adaptive immune response plus 
an anti-tumour specific response. In order to increase the OAd 
immunostimulatory properties, several genes coding cytokine such as 
IL23 (Choi et al. 2013), INF-a (LaRocca et al. 2015), CD40L (Iida et 
al. 2008) or GM-CSF (Kuryk et al. 2017) have been introduced in the 
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adenoviral back-bone; also OAds coding tumour antigens have been 
designed (Sorensen et al. 2009) in order to induce a stronger anti-
tumour specific response. The activity of genomic modified OAds 
relies on efficient transcription, often limited by the presence of Nab; 
furthermore, the genetic manipulation requires time and it is not 
compatible with the growing demand of fast personalized medicine. 
So that, in our laboratory we developed PeptiCRAd, a simply and fast 
system to adsorb the TAA on the OAd (Ad-5-D24-CpG) capsid in order 
to elicit a powerful TCD8+ anti-tumour specific activity (Capasso et al. 
2016); in the present work, we proposed an improvement of the system, 
by using TAA to induce TCD8+ and TCD4+ immune response, in order 
to have a more complete response. In addition, we are also developing 
an innovative and fast technology (PeptiCHIP) for the identification of 
TAA, in order to respond to the new horizon of personalized medicine. 
 
Since OAds increase the immune infiltration in the tumour bed, they 
represent powerful tool to induce the anti-tumour immune response; 
nevertheless, the tumour protect itself generating immunosuppressive 
microenvironment, for example over-expressing immune check point 
molecules such as PD-L1; but the combination immune checkpoint 
inhibitors (to control the immune-suppressive environment) and OAd 
(to recall the anti-tumour response) represent nowadays one of the most 
promising treatment of poor immunogenic tumours such as TNBC. 
 
 
1.4 Triple Negative Breast Cancer    
 
Triple negative breast cancer (TNBC) is still one of the most aggressive 
cancer form with no approved systemic treatment approach (Jitariu et 
al. 2017); TNBC is associated with younger age and advanced stage at 
diagnosis, increased risk of visceral metastasis and poorer outcome than 
the other breast malignant forms (Wahba and El-Hadaad 2015; 
Zeichner, Terawaki, and Gogineni 2016). As TNBC lacks of the 
expression of therapeutic targets (Foulkes, Smith, and Reis-Filho 
2010), patients do not benefit from the already approved therapy for the 
treatment of other form of breast cancer (Mousavi et al. 2013). 
In fact, TNBC is characterized by the lack of expression of estrogen 
receptor (ER), progesterone receptor (PgR) and human epidermal 
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growth factor receptor 2 (HER2) (Bianchini et al. 2016). Therefore, 
TNBC is not responsive to hormonal therapies, including aromatase 
inhibitors, SERMs (selective estrogen receptor modulators) and ERDs 
(estrogen receptor down regulators) or to anti-HER2 monoclonal 
antibody (Herceptin), all therapies approved by FDA (Wahba and El-
Hadaad 2015). In absence of an approved systemic treatment approach, 
TNBC is still treated with a combination of radiotherapy, surgery and 
chemotherapy (Bianchini et al. 2016; Wahba and El-Hadaad 2015). 
Nevertheless, TNBC represents 15-20% of total breast cancers and 
tends to be more aggressive than the others (Stagg and Allard 2013).  
 
Because of that, TNBC is still an important challenge in the research as 
in the clinical fields (Narod, Dent, and Foulkes 2015), highlighting the 
needed of a new therapeutic approach.  
 
In general, TILs have been used to evaluate the immune responsiveness 
to the tumour peptides; recent studies have evaluated the TILs in 
TNBC, demonstrating the presence of reactive T-cell to new peptides 
(named neoantigens), arising from the tumour (Garcia-Teijido et al. 
2016); the presence of TILs is considered a prognostic factor (Loi et al. 
2014): TNBC patients without treatment and positive for TILs, own 
improved overall survival, increased metastasis-free survival and 
decreased distant recurrence (Loi et al. 2014; Garcia-Teijido et al. 
2016). 
In addition, TNBC have been extensively studied for PD-L1 
expression; unlike other breast cancers, TNBC is characterized by high 
expression level of PD-L1 and also high level of TILs positive for PD-
1, making the tumour environment strongly immunosuppressive 
(Mittendorf et al. 2014; Tung et al. 2016).   
 
This line of evidence underlines the rationale of immunotherapy in the 
TNBC; in fact, several recent clinical trials based on anti-PDL1, have 
been performed in patients with metastatic TNBC, showing real 
promising results (Emens et al. 2015; Nanda et al. 2016). 
 
Following these researches, in the present work we propose to combine 
the anti-PDL1 approach with OAd, in order to elicit a specific anti-
tumour TILs infiltration and break the immunosuppressive TNBC 
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behavior. In order to have a human and clinical relevant model of 
TNBC, in the present work have been extensively used PBMCs. 
 
 
 
1.5 Peripheral Blood Mononuclear Cells  
 
Peripheral Blood Mononuclear Cells, isolated from peripheral blood, 
are any blood cells with a round nucleus from innate and adaptive 
immune system (de Mello et al. 2012); in detail, PBMCs include 
lymphocytes (T cell, B cell and NK), monocytes and DCs in according 
to the following percentage: lymphocytes 70-90%, monocytes 10-20% 
and DCs 1-2%; in turn, the lymphocytes consist of 70-85% TCD3+ 
cells, 5-10 % B-cells and 5-20% NK cells. The TCD3+ compartment is 
composed mainly of two subpopulations: TCD4+ and TCD8+ 
approximately in a 2:1 ratio. The T cells present in PBMCs population 
are mainly naïve or without effector functions (resting) and the 
percentage of T cell reactive to a specific antigen is low (Kleiveland 
2015) 
 
The PBMCs are extensively used as in vitro tool to predict the immune-
situation in vivo, showing to be a valid and predictive method (Vissers 
et al. 2013; Cribier et al. 1995); in particular, the cytokines production 
from PBMCs in vitro is one of the most used methodology to assess the 
influence on the immune-system; is common evaluating level of 
cytokines in the supernatant of cell medium by using ELISA or 
ELISPOT assay (Dias et al. 2012)  or cytokines inside the cells by using 
intracellular staining (Muris et al. 2012).  
 
 
1.6 New frontier: Personalized Cancer Immunotherapy 
 
In addition to immune editing, the cancer escapes from immune system 
recognition by using several mechanisms, that change from patient to 
patient; consequently, a personalized cancer immunotherapy is 
urgently needed in order to overcome this issue, to identify the rate-
limiting steps in any patients, to decide the strategies and finally to start 
the correct immunotherapeutic approach (Kakimi et al. 2017). In fact, 
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cancer cells, unlike their normal counterparts, undergo to several 
epigenetic and genetic alterations that result in production of aberrant 
protein termed “tumour antigens” (Gubin et al. 2015). The mutational 
burden differs among the individual cancers and can be studied by 
using a combination of next-generation sequencing and bioinformatics 
tools, allowing the identification of the most suitable targets for the 
treatment of each malignant (Bethune and Joglekar 2017; Yadav et al. 
2014). 
 
1.6.1 Tumour antigens 
 
The capacity of the immune system to fight cancer cells relies on 
presence of antigens from malignant cells and identified by T cell as 
“non-self”. 
In particular, T cells recognize peptide epitopes in the context of MHC-
I and MHC-II on the surface of cancer cells (Schumacher and Schreiber 
2015). 
These antigens are called “cancer rejection antigen” and are subdivided 
in three categories: tumour associated antigens (TAA), tumour specific 
antigens (TSA) and cancer-germline/cancer testis antigens (CTAs) 
(Gubin et al. 2015).  
 
The TAA belong to the cell genome and are overexpressed compare to 
the normal condition, for example HER2/neu in breast cancer (Baselga 
et al. 1996); even if they are self-protein, they are subject to incomplete 
central T cell tolerance, allowing the presence of reactive T cell (Gilboa 
1999).  
 
The TSA are completely absented in the cell genome and arise either 
from oncogenic viral infection or from genomic alteration that result in 
the formation of new protein sequence, called “neo-antigens”; because 
of that, TSA are not affected by central T cell tolerance, resulting more 
visible target for the immune system (Gilboa 1999) and are not shared 
among the patients.  
 
The CTA are normally expressed in the male germ in the testis and 
occasionally in fetal ovaries and trophoblast, but are not present in adult 
tissues in physiologically condition; the CTA regulation is altered in 
 
 
26 
cancer, resulting in their expression (Scanlan et al. 2002). Melanoma-
associated antigen (MAGE-A1) have been the first CTA isolated, able 
to elicit a strong T cell response (Boon and van der Bruggen 1996). 
Because of their restricted tissue expression, the CTA result strong 
immunogenic. 
Hence, TSA and CTA represents attractive targets in the field of the 
immunotherapy; in particular the “neo-antigens” are attracting the 
major attention, because as Dr. Schumacher said “The genetic damage 
that on the one hand leads to oncogenic outgrowth can also be targeted 
by the immune system to control malignancies (Schumacher and 
Schreiber 2015).”  
 
1.6.2 Identification of tumour antigens 
 
Among the tumour antigens, the “neo-antigens”, because of their 
immunogenicity, are attracting growing interest in the cancer-
immunotherapy. Nowadays, the challenge is the fast and reliable 
identification of neo-antigens, in order to design an efficient and 
personalized therapy; to this end several methods have been developed 
such as exome-sequencing, predicting peptide binding tools and 
ligandome analysis. 
 
The next-generation sequencing RNA extracted from tumour patients 
is converted in DNA and only the coding part (exome) is sequenced. 
This technology is called exome-capture and it is based on probes that 
“capture” the exon sequences; these are released, amplified, quantized 
and sequenced. This approach has been used for the identification of 
neo-antigens (Kalaora et al. 2016).   
The procedure requires three days, but often the quality/quantity of 
DNA/RNA from biopsy is not sufficient for an accurate analysis (Gubin 
et al. 2015). 
 
The Predicting Peptide binding tools Algorithms that predict the 
binding of peptides to MHC I and MHC II rely on bioinformatics and 
biochemical aspects extensively reviewed, that have been used to 
generated prediction binding programmes. First examples of these were 
SYFPEITHI, Rankpep and BIMAS; now some more accurate 
prediction algorithms are available, that resulted in the notorious 
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Immune Epitope Database and Analysis Resource (IEDB)(Soria-
Guerra et al. 2015). 
Since MHC I alleles are polymorphic (in human nearly 2500 MHC I 
allelic sequences) and the number of potential self and foreign peptides 
processed by normal, infected, or transformed cells is very large, the 
accurate prediction of which tumour-derived mutant peptide will bind 
a particular MHCI is still uncertain (Gubin et al. 2015), but still these 
programs are actually used for the design vaccination (Gubin et al. 
2014) 
 
The Ligandome analysis This method, known also as 
“immunopeptidome”, allows the characterization of natural peptides 
recognized by class I restricted cells, through the direct isolation of 
ligands from MHC I(Rammensee, Falk, and Rotzschke 1993). Briefly, 
The MHC I precipitation is performed from biopsy and next the 
complex MHC I/bound peptides are eluted, in order to collect only the 
peptides; these are resolved by liquid chromatography coupled to mass 
spectrometry in tandem (LC-MS/MS). This technology actually 
identifies about 30% of total eluted proteins and further improvements 
are needed (Kowalewski and Stevanovic 2013; Rammensee and Singh-
Jasuja 2013). 
 
The next-generation sequencing in combination with bioinformatics 
tools and ligandome analysis identify antigens to generate epitope-
based vaccine; however, fast and reliable method are needed for the 
accurate identification of neo-antigens.    
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2. AIM 
 
The main aim of the work described in this thesis is eliciting the anti-
tumour response in a murine model of Triple Negative Breast Cancer, 
combining vaccine based oncolytic adenovirus (PeptiCRAd) and anti-
PD-L1.  
In particular, the goal is  
 
1. Evaluating approaches to enhance the anti-tumor efficacy 
PeptiCRAd mediated, exploiting MHC-I and MHC-II peptides. 
 
2. Improving the response rate to checkpoint blocking antibodies 
in the context of a poor immunogenic tumor model (TNBC). 
 
3. Testing the efficacy of the co-treatment anti-PDL1 and 
PeptiCRAd in a co-culture human system of TNBC. 
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3. MATERIALS AND METHODS 
 
3.1 Cell lines and reagents 
 
Mouse breast cancer cell line (4T1) and human breast cancer cell line 
(MDA-MB-436) were purchased from the American Type Culture 
Collection (ATCC; Manassas, VA, USA) The cells were cultured in 
RPMI-1640 high glucose and DMEM low glucose respectively and 
supplemented with 10% FBS ,1% antibiotics and 1% of L-Glutamine.  
 
The human chronic myeloid leukaemia cell line (K562) and the human 
colon cancer cell line (CACO2) were purchased from the ATCC and 
cultured in RPMI-1640 low glucose and DMEM low glucose 
respectively and supplemented with 10% FBS (20% FBS for CACO-
2), 1% antibiotics and 1% of L-Glutamine. 
All cells were grown in 37°C, 5% CO2 in a humidified atmosphere. 
 
PBMC were purchased from immune Spot (Bonn, Germany) matched 
with HLA-A, HLA-B and HLA-DRB1 of MDA-MB-436 
 
Murine and human interferon g used in the vitro experiment were 
purchased from Sigma Aldrich and used both at final concentration of 
10ng/mL. 
 
The anti-mouse PDL-1(B7-H1) monoclonal antibody was purchased 
from Bio X Cell and used in animal experiment at 200µg per tumor. 
The treatment was performed every two days until the end of the 
experiment. 
 
 
3.2 Viability assay 
 
MTS assay was performed according to the manufacturer´s protocol 
(CellTiter 96 Aqueous One Solution Cell Proliferation Assay; 
Promega, Nacka, Sweden). Spectrophotometric data were acquired 
with Varioskan Flash Multimode Reader (Thermo Scientific, Carlsbad, 
CA, USA). 
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3.3 Animal Experiments and ethical permits 
 
All animal experiments were reviewed and approved by the 
Experimental Animal Committee of the University of Helsinki and the 
Provincial Government of Southern Finland. 
Female BALB/cOlaHsd mice 4-6 weeks old were obtained from 
Envigo (Harlan, USA) and used as a syngeneic mouse tumour model, 
inoculated subcutaneously with 3x105 4T1 cells in the right flank. 
The treatment was performed on established tumours. 
 
 
3.4 Flow Cytometry analysis 
 
Flow cytometry analysis was performed using Gallios (Beckman 
Coulter) flow cytometer, and FlowJo software v10 (Ashland, Oregon, 
USA). The antibodies used are the following: TruStain Fc block anti-
mouse and anti-human CD16/32 (BioLegend); FITC anti-mouse CD8 
(ProImmune); APC anti-mouse CD4 (BioLegend); PE-anti-mouse and 
anti-human CD279/PD1 (BioLegend); PE/Cy7 anti-mouse TIM3 
(BioLegend); Percp/Cy5.5 anti-mouse CD3e (BioLegend); APC anti-
mouse H2Kd (BioLegend); APC anti-mouse I/A-I/E (BioLegend); PE-
anti-human and mouse CD274 B7-H1 (PDL-1), PE anti-human HLA-
A, B, C (BioLegend). 
 
All procedures were performed according to the manufacturer´s 
recommendation. 
 
 
3.5 Intracellular staining for FOXP3 
 
The intracellular staining in mice tumour samples were performed 
according to the manufacturer´s protocol (eBioscience) and data 
acquired using BD-LSRF Fortessa (BD cell analyzer). 
The staining for Treg was performed using the following antibodies: PE-
Foxp3 (eBioscience), Percp/cy5.5-CD3e (BioLegend) and Pe-
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Cyanine7-CD4 (eBioscience) and the data were analyzed using FlowJo 
software v10 (Ashland, Oregon, USA). 
 
 
3.6 MDSCs panel analysis 
 
Mice tumour samples were staining using FITC-Cd11b (BD 
Pharmingen), PE-Ly6G (BD Pharmingen) and APC-Ly6C (BD 
Pharmingen) according to the manufacturer´s recommendation. The 
data were acquired using BD Accuri 6C plus (BD) and the data 
analyzed using FlowJo software v10 (Ashland, Oregon, USA). 
 
 
3.7 PeptiCrad complex formation 
 
Oncolytic adenovirus and polyK epitope (Ontores, Zhejiang, China) 
were mixed to prepare the PeptiCRAd complex. We mixed polyK 
epitope with Ad-5-D24-CpG for 15 minutes at room temperature and 
after that, we use this complex to treat the mice. 
For the in vivo experiments, we combined 7 µg for each epitope with 
1x109 vp for each tumour.  
 
In the group called PeptiCRAd-D.C. to obtain the same final amount of 
epitope, we combined 3.5 µg for each epitope with 1x109 vp for each 
tumour;  
 
In the group called PeptiCRAd-S.C., we combined 7 µg for each 
epitope to induce TCD4 subtype response with 1x109 vp for each 
tumour in one eppendorf and 7 µg for each epitope to induce TCD8 
subtype response 1x109 vp for each tumour in another eppendorf. After 
the 15 minutes, we took the half amount of each eppendorf and we 
combined them together. 
 
 
3.8 HLA genotyping 
 
The DNA extraction was performed according to the manufacturer´s 
protocol (QIAamp DNA Mini Kit 50 Qiagen); the Finnish Red Cross 
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analyzed the HLA-A, B and DRB1 on high resolution (4digit Sanger´s 
sequencing).  
 
 
3.9 Elisa IL-2 
 
The IL-2 level in the cell culture supernatant from PBMCs were 
measured by ELISA (R&D Systems, Minneapolis, MN, USA) 
according to the manufacturer´s directions.   
 
 
3.10 Statistical Analysis  
 
Statistical analysis was performed using Graphpad Prism 6.0 software 
(Graphpad Software Inc., La Jolla, CA USA). 2way ANOVA with 
Tukey´s multiple comparisons test was used and P<0.05 was 
considered statistically significant. 
All results are expressed as the mean ± standard error of the mean 
(SEM). 
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4. RESULTS 
 
4.1 4T1 and MDA-MB-436 represent solid model for an 
immunotherapeutic approach. 
 
Cancer cells escape the immune recognition and destruction by several 
mechanisms. One of these is the down regulation of MHC-I (HLA-A, 
B and C in human)  (Campoli and Ferrone 2008) and  the up-regulation 
of PD-L1 (Robainas et al. 2017). To assess the feasibility of our 
immunotherapeutic approach, we needed solid model of TNBC cell 
line. 
 
To this end, we characterized 4T1 and MDA-MB-436, respectively a 
murine and human TNBC cell line, for the expression of MHC-I, MHC-
II and PD-L1. 
 
First, we performed a flow cytometry analysis in 4T1 cell line 
stimulated and not stimulated overnight with IFN-g ,to evaluate the 
levels of MHC-I, MHC-II and PD-L1.  
 
The use of IFN-g is justified to recreate the tumour microenvironment, 
in which it has an antitumor potential by inducing MHC, but at same 
time induces the expression of PD-L1 (Parker, Rautela, and Hertzog 
2016) . As attended, in presence of IFN-g the expression of MHC I 
(Fig.1A), MHC II (Fig.1B) and PDL-1 (Fig.1C) is higher compared to 
the cells without stimulation, but it is interesting that also in absence of 
IFN-g the cells showed basic levels of MHC-I, MHC-II and PD-L1; 
thus, the 4T1 cells resulted a valid model for an immunotherapeutic 
treatment.  
 
Because the in vitro levels of MHC-I, MHC-II and PD-L1 in 4T1 cells 
may not reflect the in vivo situation, we decided to detect the level of 
MHC-I and PDL-1 in cells from mice bearing 4T1 tumours, confirming 
the in vitro data previously described (Fig. 1D and 1E). 
Furthermore, the in vivo analysis in 4T1 showed higher TILs PD1+ in 
tumours compared to spleens and lymph nodes (Fig. 1F and 1G).   
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Hence, in according to the data aforementioned, 4T1 cell line represents 
a valid model to evaluate the efficacy of an immunotherapeutic 
approach.  
 
The next step of all the experiments described in this thesis is the 
clinical translation; because of that, we selected MDA-MB-436 and 
also in this case, we analysed and confirmed the expression of HLA-A, 
B, C and PD-L1. (Fig. H and I). These first set of experiments defines 
4T1 and MDA-MB-436 as rationale model for the following 
experiments.  
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Figure1 4T1 and MDA-MB-436 immune characterization. MHC-I 
(A), MHC-II (B) and PD-L1 (C) in 4T1 cell line are described. The 
cells were seeded at final number of 3x105 in 5mL and the day after 
IFN-g was added to medium at final concentration of 10 ng/mL 
overnight. The following day we performed flow cytometry analysis 
using anti-mouse APC-H2Kd, anti-mouse APC-MHCII and anti-mouse 
PE-PDL1  
Expression levels of MHC-I (D) and PD-L1 (E) in tumors from mice 
bearing 4T1 tumors and T cell infiltration PD1+ in tumors, spleens and 
lymph nodes from mice bearing 4T1 tumor are presented (F and G). 
We performed a flow cytometry analysis in tumors, spleen and lymph 
node samples collected from mice and frozen. We used anti-mouse PE-
PD1, anti-mouse Percp/Cy5.5 CD3e, anti-mouse FITC-CD8 and anti-
mouse APC- CD4. 
MDA-MB-436 showed high level of HLA-A, B, C (H) and PD-L1 (I). 
We seeded the cells at final number of 4x105 cells and the day after we 
stimulated the cells over night with human INF-g at final concentration 
of 10 ng/ml. We performed the flow cytometry analysis using anti-
human PE-HLA-A, B, C and PE-CD274 B7-H1 (PD-L1) (statistical 
analysis one-way Anova and unpaired t test P<0.05). 
 
 
4.2 Ad-5-D24-CpG cytotoxic effect is identical to Ad-5/3-D24 in 
murine and human TNBC cell line.  
 
PeptiCRAd is based on Ad5-D24-CpG, that bears a 24bp deletion in 
E1A gene and CpG rich islands to increase the immunogenicity, trought 
the Toll Like Receptor 9 (TLR9) stimulation (Cerullo et al. 2012). 
 
First, we investigated the cell-killing efficacy of Ad5-D24-CpG in 4T1 
and MDA-MB-436; we compared its efficacy to Ad-5/3-D24, already 
used and validated in human model of TNBC (Bramante et al. 2016). 
 
Since human adenovirus not produce infection viral progeny by using 
murine cells line (Zhang et al. 2015), as expected Ad-5-D24-CpG and 
Ad-5/3-D24 at 1 vp/cell and 10 vp/cell showed killing activity in human 
MDA-MB-436 (Fig.2A) , but not in 4T1 (Fig.2B). 
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In the future, when we will translate this treatment in clinical, we will 
take advantages by combining the boosting of immune system induced 
by PeptiCRAd with the intrinsic viral oncolytic activity. 
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Figure2 Ad-5-D24-CpG and Ad-5/3-D24 showed identical killing-
cell activity. We tested both viruses in human MDA-MB-436 and 
murine 4T1 cell line, by using 0.1vp/cell, 1 vp/cell, 10vp/cell, 100 
vp/cell and 1000 vp/cell concentration; in addition, we included one 
condition without virus as control. (A)Six days post-infection, already 
at 1 and 10 vp/cell both viruses showed killing activity in MDA-MB-
436. (B) As expected, the same killing is not observed in 4T1 cell line. 
The data are shown as mean + SEM (n=3). 
 
 
 
4.3 The TCD4 and TCD8 subtypes responses synergistically elicit 
antitumor response in early stage of TNBC. 
 
In these set of in vivo experiments, we evaluated the anti-tumour 
efficacy of different PeptiCRAd preparations in TNBC.  
 
First, we selected and analysed a list of peptides from literature (Kreiter 
et al. 2015; Singh et al. 2013; Gravekamp et al. 2008; Song et al. 2014). 
Indeed, we used the bioinformatics on-line platform IEDB to predict 
the binding affinity for H2Kd (MHC-I) and MHC-II (Table1). Next, 
we prepared diverse PeptiCRAd complexes coated either with peptides 
MHC-I (i.e., PeptiCRAD-CD8) or MHC-II (i.e., PeptiCRAd-CD4) 
restricted. Furthermore, we coated PeptiCRAd with both peptides 
MHC-I and II restricted or loading them on the same adenovirus (i.e., 
PeptiCRAd-D.C.) or by mixing equal concentration of adenovirus 
covered with the peptides (i.e., PeptiCRAd-S.C.). 
 
Balb/c immunocompetent mice engrafted with 4T1 received 
PeptiCRAd intratumourally at 9, 11 and 13 days after tumour 
implantation; at day 15 we observed significantly difference in the 
tumour’s growth in the PeptiCRAd-D.C. group compared to the Mock 
(Fig.3A and B); interestingly, PeptiCRAd-D.C. was more effective 
also compared to PeptiCRAd-S.C. (Fig.3C). Since the previously 
analysis showed a strong immune suppressive component in 4T1, as 
expected, at the end of the experiment the average volume of the 
tumours in all group was not significantly lower than the Mock. 
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Next, we evaluated the immunological background in lymph nodes and 
tumours from the treated groups. In particular, we analysed the 
exhausted phenotype of T-cell, using PD1 and TIM3 as marker to verify 
possible difference among the groups. In the lymph nodes (Fig. 3D) 
and in tumours (Fig.3C) the antigen experienced T cells (PD1+ TIM3-) 
were similar, confirming that the immunosuppressive environment 
overcome the benefit PeptiCRAd induced.  
These results are coherent with the widely characterization of the 
pathway PD1/PD-L1 in TNBC and highlight the beneficial use of PD-
L1 blockade in this cancer disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 We added poly-lysine (polyK) chain to the amino acidic 
sequence to increase the net charge of the peptide to +6 mV at neutral 
pH, in order to allow electrostatic interaction with adenovirus capsid 
and the formation of the PeptiCRAd complex. 
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Figure 3 Antitumor activity of different PeptiCRAd formulations 
and immunological background analysis. (A) Balb/c mice (n=7) 
received 3x105 4T1 cells in the right flank. Treatments were initiated 
on established tumors (9 days after implantation) and the mice were 
treated three times (on days 9, 11 and 13, black arrows). The average 
volume is represented in the tumour´s growth curve as mean ± SEM 
(statistical analysis 2way ANOVA with Tukey´s multiple comparisons 
test, P<0.05). After 15 days, the tumor volume in the group PeptiCRAd-
D.C. was significantly lower compared to Mock. (B and C) Oncolytic 
adenovirus double coated efficiently control tumor growth compared to 
the mixture of equal concentration of oncolytic adenovirus with MHC-
I and MHC-II peptides. The average volume is represented in the 
tumour´s growth curve as mean ± SEM (statistical analysis 2way 
ANOVA with Tukey´s multiple comparisons test, P<0.05). (D) At the 
end of the experiments the organs were collected and analysis were 
performed. Per each group, five draining lymph nodes were pulled 
together and the analysis executed in duplicate. The antigen 
experienced T-cells (PD1+ TIM3-) is showed (graphs represented as 
median). (E) Tumors were also analyzed (tumors n. 4-5, graphs 
represented as median) for the T cell PD1+TIM3-. 
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4.4 PD-L1 blockade and PeptiCRAd synergistically enhance anti-
tumour efficacy against TNBC by modulating the 
immunosuppressive environment. 
 
The PD-1/PD-L1 blockade usually reverts or prevents the T-cell 
exhaustion, since PD-L1 modulate the active immune response in the 
“tumour bed” (Chen and Mellman 2013). To further investigate the 
anti-tumour efficacy of PeptiCRAd in combination with anti-PDL1, we 
implanted 3x10 5  4T1 cells in the right flank of Balb/c mice and we 
started the treatments on the established tumours. The treatment groups 
included anti-PDL1 in absence (i.e.,a-PDL1) or in presence of 
PeptiCRAd double coated (i.e., PeptiCRAd-D.C. + a-PDL1). 
  
Until the end of the experiment, the co-treatment PeptiCRAd-D.C./ 
anti-PDL1 induced statistically reduction of the tumour growth 
(Fig.4A) as showed also by the single tumour growth per each mouse 
treated (Fig.4B).  
 
At the end of the experiment, tumours were collected and analysed for 
immunological studies. PD-L1 alone was not able to induce T cell 
infiltration; instead, the combination PD-L1/PeptiCRAd-D.C. drove 
TCD8+ and TCD4+ in the tumour tissue (Fig. 4C). 
 
Previous works highlight the strong immunosuppressive environment 
in 4T1 mammary carcinoma model in which, among the other 
mechanisms, myeloid-derived suppressor cells (MDSCs) are involved 
(Ali et al. 2014; Bunt et al. 2006; Youn et al. 2008). In according to 
these studies, we decided to verify the MDSCs infiltration in the tumour 
samples from treated mice; the MDSCs are a heterogeneous population 
of bone marrow-derived myeloid cells that co-express the CD11b and 
Gr1 surface markers. Gr1 is made of Ly6C+ and Ly6G+ and the MDSCs 
are subdivided in two populations: M-MDSC (Ly6C+), the monocyte 
population and PMN-MDSC (Ly6G+), the polymorph nuclear 
population.  
 
In a first set of analysis, the absence or presence of Ly6C and Ly6G, 
identified two sub populations: Cd11b+Ly6C+ (M-MDSC) and 
Cd11b+Ly6G+ (PMN-MDSC). Interestingly, the PMN-MDSCs 
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population in the group PeptiCRAd-D.C.+aPDL1 is statistically 
predominant compared to Mock (Fig.4D). 
 
In the second step, we isolate the neutrophil population from the PMN 
population. Following previous analysis (Ali et al. 2014), we designed 
the neutrophil as Ly6Ghigh and Ly6C intermediate/high   and the PMN 
population as Ly6Ghigh and Ly6C-/low  .  
 
The neutrophil population in tumours from PeptiCRAd-D.C.+aPDL1 
group was statistically predominant compared to the Mock (Fig.4E). 
Knowledge surrounding neutrophils are still in progress and needs 
clarification; however, it has been demonstrated that they can oppose 
the tumour growth through their cytotoxic activity in mice (Fridlender 
et al. 2009).  
 
Finally, we analysed the Treg population (TCD4+Foxp3+) in these 
tumour samples. The PD-L1 blockade in presence of PeptiCRAd-D.C 
caused a depletion of Treg population compared to the group treated 
with only anti-PDL1 and Mock (Fig.4F). 
 
These data demonstrate that the combination PeptiCRAd/PDL1 
blocking enhances the tumour immune infiltration and allows 
controlling the strong immune suppressive environment in 4T1 tumour. 
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Figure 4 Anti-tumour activity PD-L1 blockade and PeptiCRAd 
mediated, and immune modulation in tumour microenvironment. 
(A) Balb/c (n=8 per group) received 3x105 4T1 cells in the right flank 
and the treatment started on established tumour. The tumour´s growth 
is represented as mean ± SEM (statistical analysis 2way ANOVA with 
Tukey´s multiple comparisons test, P<0.05). At the end of the 
experiment, the tumour’s growth in PeptiCRAd+aPDL1 group was 
statistically lower compared to Mock. (B) The single tumour growth 
curves for single mouse and one graph for each group are presented. 
Responders are defined in percentage (displayed next to each graph) as 
mice that show an absolute volume lower than 200 mm3. (C) Flow 
cytometry analysis of CD4 and CD8 T cells in tumour samples from 
the animal groups is presented. (D) At the end of the experiment the 
tumours were collected and analysed for the PMN-MDSCs infiltration. 
The data are showed as bar (mean ± SEM) and median (statically 
analysis unpaired t-test P<0.05). (E) The analysis was repeated 
considering the intermediate value of Ly6C+ signal, identifying the 
neutrophil population. The data are showed as bar (mean ± SEM) and 
median (statically analysis unpaired t-test P<0.05). (F) Relative 
percentage of subset of TCD4 FoxP3 for each group is described. 
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4.5 PeptiCRAd pulsed PBMCs enhance human TNBC killing in a co-
culture system. 
 
To move forward in a relevant clinical model, we performed an in vitro 
T cell killing assay, in which we used peripheral blood mononuclear 
cells (PBMCs). 
First, we needed PBMCs with HLA A, B and DRB1 matched with the 
MDA-MB-436 genotype.  
 
To this end, genomic DNA from MDA-MB-436 was isolated and 
analysed (Fig.5A-B).  
Next, we stimulated the T-cells in PBMCs HLA matched versus 
specific and well know tumour associated antigens (TAA) from human 
TNBC (Cabezon et al. 2013; Mathe et al. 2015; Stagg and Allard 2013). 
 
It is well know the difficult to obtain the T-cell proliferation in vitro in 
PBMCs in response to an exogenous antigen (Kennell, Gould, and 
Salaman 2014); in order to overcome the problem, we cultured all the 
PBMCs in this work with human IL-2 plus PeptiCRAd in according to 
the following groups:  
PBMCs pulsed with either MAGEA4-PeptiCRAd or with NYBR1-
PeptiCRAd or PeptiCRAd-P001; furthermore, we had a group pulsed 
with MAGEA4+NYBR1-PeptiCRAd. In addition, we used as control 
PBMCs pulsed with OAd-5-D24-CpG (group called AD) only and the 
PBMCs without PeptiCRAd stimulation (group called IL2). 
 
The peptide called P001 is the result of the ligandome analysis, in an 
improved version set up in our laboratory. 
 
After three days of stimulation, we added the PBMCs to MDA-MB-
436 at ratio 1:10. At day 6 MTS assay was performed to assess MDA-
MB-436 viability (Fig.5C). Statistically killing T-cell activity was 
observed in the MDA-MB-436 from the groups MAGE-A4 
PeptiCRAd, NYBR1+MAGEA-4 PeptiCRAd and P001 PeptiCRAd 
compared to the controls. 
 
Finally, in order to demonstrate the T-cell activation in response to 
PeptiCRAd, we measured the IL-2 levels by 
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supernatant. The results shown higher IL-2 level in all the conditions 
compared to the control groups, confirming the T-cell activation 
antigen specific. (Fig.5D). 
 
Our data demonstrate that PeptiCRAd prime T-cell population in 
response to TAA from TNBC, a poor immunogenic cancer. 
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Test / Method Parameter Result 
HLA-A typing, 
high resolution A 01:01  
HLA-B typing, 
high resolution B 08:01 
HLA-DRB typing, 
high resolution DRB1 03:01 
B 
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Figure 5 Genomic DNA isolated from MDA-MB-436 using and T-
cell killing assay in co-culture system. (A) DNA quality was verified 
by running the DNA genomic digested with DNAse (lane A) and 
without DNAse (lane B). As attended the DNA genomic (lane B) is 
about 30-50Kb. (B)The Finnish Red cross performed the Sanger´s 
sequencing on high resolution (4 digit) for HLA-A, B (MHC-I) and 
DRB1(MHC-II) (Fig.5B). (C)T-cell in vitro killing assay using 
PBMCs pulsed with PeptiCRAd. PBMCs were pulsed with PeptiCRAd 
as described and percentage of the killing is represented as bar of mean 
± SEM. (D) Representative imagines of MDA-MB-436 and MDA-MB-
436+PBMCs are reported. (E) IL-2 level from supernatant are shown 
and are represented as bar of mean ± SEM.  
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5.DISCUSSION 
 
The TNBC is still one of the most aggressive cancer form with no 
approved systemic treatment approach (Jitariu et al. 2017). TNBC is 
associated with younger age and advanced stage at diagnosis, increased 
risk of visceral metastasis and poorer outcome (Wahba and El-Hadaad 
2015; Zeichner, Terawaki, and Gogineni 2016). Because TNBC lack of 
the expression of therapeutic targets(Foulkes, Smith, and Reis-Filho 
2010), patients do not benefit from the already approved therapy for the 
other form of the breast cancers (Mousavi et al. 2013). Therefore, 
TNBC is still an important challenging in the research as in the clinical 
field (Narod, Dent, and Foulkes 2015). 
 
Recent studies underline that patients positive for tumour infiltrating 
lymphocytes respond to PD-L1 blockade. (Garcia-Teijido et al. 2016; 
Castaneda et al. 2016; Adams et al. 2014). Nevertheless, many patients 
fail to respond, because of the immunosuppressive environment and the 
absence of T cell infiltration, suggesting that patients can benefits from 
strategies that enhance immune response (Dushyanthen et al. 2015). 
The boosting of the immune system and the blocking of the 
immunosuppressive signal in the tumour environment represent 
nowadays one of the most promising treatment (de la Cruz-Merino et 
al. 2013). 
 
To this end, we decided to combine PeptiCRAd with anti-PDL1. 
PeptiCRAd is a platform based on peptide-coated oncolytic adenovirus, 
already tested in other tumour forms (Capasso et al. 2016). The 
platform combines the adjuvancy of the virus with the immunological 
targeting of tumour-derived peptides, converting the powerful anti-
viral immune response obtained with viral vaccines into a more 
efficient anti-tumoural response. In this study, for the first time, we 
used the platform in a cancer model traditionally considered poor 
immunogenic: TNBC; furthermore, we explored not only the TCD8+ 
subtype response but also the TCD4+, testing different PeptiCRAd 
peptides preparations.  
 
Tumour escape the immune system down-regulating MHC-I and up-
regulating PD-L1. 
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Thus, we first chose and characterized 4T1 and MDA-MB-436, 
respectively a murine and human cell line, for the expression of MHC 
I, MHC II and PD-L1 to verify their use as a rational model for an 
immunotherapeutic approach. Both cell lines showed high expression 
level of MHC-I, MHC II and PD-L1 and furthermore were solid model 
for an immunotherapeutic approach. 
Next, we demonstrated that the oncolytic activity of Ad5-D24-CpG in 
4T1 and MDA-MB-436 cell lines was similar to the already validated 
Ad-5/3-D24 in human model of TNBC. As expected, in the murine cell 
line we did not observe the cytopathic effect. Thus, all the effects 
described in the murine TNBC model were associated to the delivery 
action of OAd and the boosting of the immune system for the peptides 
loaded on the viral capsid. In clinical, the therapy could benefit also 
from the oncolytic activity of the OAd. 
 
To characterize the anti-tumour activity of PeptiCRAd in vivo, we used 
mice engrafted with aggressive TNBC cell line 4T1 and we targeted 
antigens already validated in the literature  (Kreiter et al. 2015; Singh 
et al. 2013; Gravekamp et al. 2008; Song et al. 2014). To further 
investigate TCD8+ and TCD4+ subtype responses, the “two harms” of 
the immune system, we selected antigens recognized in MHC complex 
I and II. The IEDB analysis helped us to selected the epitopes with the 
best predict binding capability to the MHC I and II. Mice treated with 
a combination of Ad5-D24-CpG covered with antigens to induce 
TCD8+ and TCD4+ subtype responses showed a significantly decreased 
tumour growth, but at the end of the experiment there were no 
difference among the groups in the size. The analysis of immunological 
background highlighted the strong immune- suppressive environment. 
 
These results confirm  TNBC as a poor immunogenic cancer model and 
are consistent with current knowledge about the pathway PD1/PD-L1, 
in particular with the widely characterization of PD-L1 in the TNBC 
patients (Chen et al. 2013). In fact, a preliminary and successful clinical 
trials with anti-PDL1antibody, called MPDL3280A and already used 
also in a successful clinical trial with metastatic bladder cancer(Powles 
et al. 2014) , was performed in patients with a metastatic form of TNBC 
(Emens et al. 2015), confirming that TNBC is a good candidate for an 
immunotherapy approach.  
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Because of that, we decided to combine PeptiCRAd-D.C. with 
monoclonal antibody anti-PDL1. We found that targeting tumour 
antigens to induce TCD4+ and TCD8+ subtype responses in 
combination with anti-PDL1 decreases the tumour growth rate; next, 
the immunological analysis performed by using tumour samples 
revealed a higher frequency of TCD8+ in tumour sample from 
PeptiCRAD+aPDL1 compared to the Mock and to aPDL1.  
 
We decided to further investigate the immunological status of the 
tumour samples. In particular, we focused the attention on myeloid-
derived suppressor cells (MDSCs), a population that block the 
activation of anti-tumour TCD4+ /TCD8+ activity (Srivastava et al. 
2010) and described in different tumour types and positively associated 
to the metastatic tumour phenotype (Ouzounova et al. 2017). In 
particular the 4T1 tumour have been previously reported as a tumour 
model characterized by MDSCs infiltration.  (Youn et al. 2008; Danilin 
et al. 2012). Following these studies, we analyzed in our tumour 
samples the MDSCs population and we observed that the PMN-
MDSCs population resulted statistically higher in the group 
PeptiCRAd+aPDL1 compared to the Mock. The PMN-MDSCs are the 
predominant population in the MDSCs population and it is associated 
to poorer diagnosis in the patient (Wynn 2013; Binsfeld et al. 2016) .  
However, analysing the low/intermediate expression level of Ly6C+ 
cells in the PMN population, in according to literature (Ali et al. 2014)  
we identified the neutrophils population that resulted higher in the 
PeptiCRAd+aPDl1 group compare to the Mock.  
The role of neutrophils in cancer is still unclear, but it has been 
demonstrated that they can oppose the tumour growth through their 
cytotoxic activity in mice (Fridlender et al. 2009). 
 
Finally, in order to validate PeptiCRAd in a relevant clinical model of 
human TNBC, we designed an in vitro T-cell killing assay; in 
particular, we selected PBMCs matched with the same HLA-A, B and 
DRB1 genotype of the human cell line MDA-MB-436. When we added 
the PBMCs pulsed with PeptiCRAd on the top of MDA-MB-436, we 
observed tumour cell killing, demonstrating that the use of PeptiCRAd 
created specific T-cell anti-tumour response, also confirmed by the IL2 
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level in the supernatant of the killing assay. One peptide, used in this 
experiment, has been chosen by using the ligandome analysis, method 
for identifying epitopes MHC I restricted and improved in our 
laboratory.  
 
Nowadays, the identification of new epitopes to use in cancer vaccine 
is limited by the available technology; for example, the actual genomic 
and proteomic technologies allow to isolate the over- /under- expressed 
proteins, but are unable to detect low proteins, often processed and 
presented in the MHC-I complex that induces a strong T cell response 
(Comber and Philip 2014). The most promising method to identify truly 
relevant tumour antigens is the direct analysis of the MHC-I peptides 
complex. To this end, we set up and improved the ligandome analysis 
for the direct isolation of the peptides from MHC-I. 
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6.CONCLUSIONS 
 
 
In conclusion, PeptiCRAd is a versatile and rapid system to adsorb 
tumour-specific major histocompatibility complex class I (MHC-I) 
peptides onto the viral surface to drive the immune response toward the 
tumour epitopes (Capasso et al. 2016). Already validated in other 
tumour models, in this study we adapted the same platform in a 
challenging model of TNBC and for the first time we explored also the 
use of tumour specific MHC-II restricted peptides, observing that 
vaccine coating with a combination of MHC-I and -II-restricted 
peptides is more effective than the previously that used MHC-I 
restricted peptides coating, leading to a further improvement of the 
system. Therefore, PeptiCRAd has a clear advantage: it can harness 
both arms of the immune system and as oncolytic agent induce lysis of 
the human tumour cells. 
 
Moreover, we successfully associate the antigen-specific T cell 
responses PeptiCRAd mediated with the PD-L1 blockade in a poor 
immunogenic tumor, thus providing a strong rationale for a 
combinatorial approach. 
 
In the future, the advance in the ligandome and RNAseq for identifying 
neo-antigens and their application in versatile platform, such as 
peptiCRAd, will open new possibilities in the co-treatment with 
checkpoint inhibitors to treat cancer patients. 
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7.APPENDICS 
 
FDA approves first-of-its-kind product for the treatment of 
melanoma: 
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm
469571.htm 
 
Immune Epitope Database and Analysis Resource 
http://www.iedb.org/ 
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